LYAR

Across TCGA pan-cancer cohorts, LYAR Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LYAR data layer compared with 30 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LYAR Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LYAR expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, UCEC, and LUSC are the cancer types where LYAR Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.153	0.750	<.001	30	view →
UCEC	DFS	Median	III,IV	1.000	0.538	.028	22	view →
LUSC	OS	Median	II,III,IV	0.086	0.733	<.001	14	view →
THCA	OS	Median	All	0.323	0.955	<.001	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LYAR–LUAD (OS)

Open the LUAD breakdown →